- Rite Aid Corp RAD reported a second-quarter FY23 sales decline of 3.5% year-on-year to $5.90 billion, beating the consensus of $5.77 billion.
- RAD attributed the top-line decline to a reduction in revenue from COVID vaccines and testing, store closures, and a planned loss of covered lives at Elixir.
- Segment Revenue: Retail Pharmacy declined 1.1% to $4.2 billion and Pharmacy Services fell 9% to $1.7 billion.
- Selling, general and administrative expenses fell 5.8% to $1.2 billion.
- Net loss for the quarter widened to $(331.3) million.
- The company held $46.8 million in cash and equivalents as of August 27, 2022.
- Adjusted EBITDA of $78.5 million decreased 26.1% Y/Y.
- Adjusted EPS loss of $(0.63) missed the analyst consensus of $(0.55).
- CEO Heyward Donigan said, "As we look to the second half of the year, we expect continued pressure on consumer spending and supply chain challenges."
- Outlook: Rite Aid maintains its outlook for FY23 revenues and lowers its outlook for net loss and Adjusted EBITDA.
- It sees total revenues of $23.6 billion - $24.0 billion against the consensus of $23.36 billion.
- Rite Aid sees FY23 adjusted EPS loss $(1.52) - $(0.97) versus the estimate of $(1.39). RAD previosuly expected adjusted loss per share of $(1.19) - $(0.66).
- The company lowered FY23 adjusted EBITDA outlook to $450 million - $490 million from the previously expected $460 million - $500 million.
- Price Action: RAD shares are trading lower by 29.2% at $4.97 on the last check Thursday.
- Photo Via Company
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
